Clinical Research Directory

Inclusion Criteria: * Age \> 18 years * Any gender * Patients will have had no therapy for their thyroid nodule prior to enrollment * Negative urine pregnancy test within 48 hours before the administration of radiopharmaceutical in women of childbearing potential * Follicular neoplasm or suspicious of follicular neoplasm, cytopathology on biopsy of thyroid nodule * Any outside fine needle aspiration (FNA) reports are to be reviewed by a Mayo pathologist * Nodules 1-4 cm with solid appearance on ultrasound * Ultrasound images and report documented in medical record, including the size of the nodule and location (upper, mid or lower portion of the thyroid lobe) * At least 2/3 of either thyroid lobe without nodules should be present to allow for the measurement of uptake in unaffected thyroid tissue * Thyroid stimulating hormone (TSH) 0.3-3.0 mIU/L * Patient is scheduled or being considered for surgical resection of the nodule * I-123 planar and Single Photon Emission Computed Tomography (SPECT)/Computed Tomography (CT) can be scheduled at least 2 days after biopsy and before surgery Exclusion Criteria: * Recent iodinated contrast, including intravenous (IV) and oral CT contrast or interventional vascular or cardiac study (within 6 weeks) * Hurthle cell adenoma * Current thyroid hormone supplementation * Current use of anti-thyroid medications (methimazole or propylthiouracyl) * Less than 2 days after thyroid nodule FNA/biopsy * Presence of another nodule of similar size in the same area of thyroid lobe, which could impair localization of the nodule on SPECT/CT images * Less than 2/3 of normal thyroid tissue present in either thyroid lobe without nodules * Positive pregnancy test * All women who are breastfeeding